Andrew Reardon's most recent trade in Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B was a trade of 5,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on June 30, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2026 | 5,000 | 34,444 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 30 Jun 2026 | 5,000 | 46,514 (0%) | 0% | 52.3 | 261,350 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 311.72 per share. | 30 Jun 2026 | 1,119 | 44,895 (0%) | 0% | 311.7 | 348,815 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 312.28 per share. | 30 Jun 2026 | 1,081 | 43,814 (0%) | 0% | 312.3 | 337,573 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 315.78 per share. | 30 Jun 2026 | 900 | 42,114 (0%) | 0% | 315.8 | 284,200 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 313.46 per share. | 30 Jun 2026 | 700 | 43,114 (0%) | 0% | 313.5 | 219,420 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 317.15 per share. | 30 Jun 2026 | 600 | 41,514 (0%) | 0% | 317.2 | 190,291 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 308.99 per share. | 30 Jun 2026 | 396 | 46,118 (0%) | 0% | 309.0 | 122,359 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Other type of transaction at price $ 160.71 per share. | 30 Jun 2026 | 132 | 41,514 (0%) | 0% | 160.7 | 21,214 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 310.20 per share. | 30 Jun 2026 | 104 | 46,014 (0%) | 0% | 310.2 | 32,261 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 314.58 per share. | 30 Jun 2026 | 100 | 43,014 (0%) | 0% | 314.6 | 31,458 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2026 | 5,000 | 39,444 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 01 Jun 2026 | 5,000 | 46,382 (0%) | 0% | 52.3 | 261,350 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 225.97 per share. | 01 Jun 2026 | 1,432 | 43,782 (0%) | 0% | 226.0 | 323,585 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 229.47 per share. | 01 Jun 2026 | 1,216 | 41,582 (0%) | 0% | 229.5 | 279,033 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 225.20 per share. | 01 Jun 2026 | 677 | 45,214 (0%) | 0% | 225.2 | 152,459 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 228.57 per share. | 01 Jun 2026 | 584 | 42,798 (0%) | 0% | 228.6 | 133,487 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 223.95 per share. | 01 Jun 2026 | 491 | 45,891 (0%) | 0% | 223.9 | 109,958 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 226.78 per share. | 01 Jun 2026 | 400 | 43,382 (0%) | 0% | 226.8 | 90,712 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 230.41 per share. | 01 Jun 2026 | 200 | 41,382 (0%) | 0% | 230.4 | 46,082 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 May 2026 | 5,000 | 44,444 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 01 May 2026 | 5,000 | 46,382 (0%) | 0% | 52.3 | 261,350 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 232.92 per share. | 01 May 2026 | 1,420 | 42,182 (0%) | 0% | 232.9 | 330,749 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 228.75 per share. | 01 May 2026 | 932 | 44,850 (0%) | 0% | 228.8 | 213,198 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 234.02 per share. | 01 May 2026 | 800 | 41,382 (0%) | 0% | 234.0 | 187,214 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 232.04 per share. | 01 May 2026 | 780 | 43,602 (0%) | 0% | 232.0 | 180,991 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 227.45 per share. | 01 May 2026 | 600 | 45,782 (0%) | 0% | 227.5 | 136,470 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 230.87 per share. | 01 May 2026 | 370 | 44,382 (0%) | 0% | 230.9 | 85,422 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 229.70 per share. | 01 May 2026 | 98 | 44,752 (0%) | 0% | 229.7 | 22,511 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 01 Apr 2026 | 5,000 | 46,382 (0%) | 0% | 52.3 | 261,350 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2026 | 5,000 | 49,444 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 199.72 per share. | 01 Apr 2026 | 1,302 | 44,620 (0%) | 0% | 199.7 | 260,038 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 200.94 per share. | 01 Apr 2026 | 1,238 | 43,382 (0%) | 0% | 200.9 | 248,767 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 203.22 per share. | 01 Apr 2026 | 963 | 41,719 (0%) | 0% | 203.2 | 195,703 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 201.90 per share. | 01 Apr 2026 | 700 | 42,682 (0%) | 0% | 201.9 | 141,328 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 198.85 per share. | 01 Apr 2026 | 460 | 45,922 (0%) | 0% | 198.9 | 91,471 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 204.50 per share. | 01 Apr 2026 | 337 | 41,382 (0%) | 0% | 204.5 | 68,917 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 04 Mar 2026 | 5,000 | 41,869 (0%) | 0% | 52.3 | 261,350 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 5,000 | 54,444 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 208.12 per share. | 04 Mar 2026 | 1,446 | 38,011 (0%) | 0% | 208.1 | 300,939 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 208.87 per share. | 04 Mar 2026 | 1,142 | 36,869 (0%) | 0% | 208.9 | 238,532 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 207.01 per share. | 04 Mar 2026 | 612 | 39,457 (0%) | 0% | 207.0 | 126,689 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 205.18 per share. | 04 Mar 2026 | 460 | 40,409 (0%) | 0% | 205.2 | 94,382 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 206.37 per share. | 04 Mar 2026 | 340 | 40,069 (0%) | 0% | 206.4 | 70,165 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 201.70 per share. | 04 Mar 2026 | 300 | 41,069 (0%) | 0% | 201.7 | 60,510 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 199.96 per share. | 04 Mar 2026 | 207 | 41,462 (0%) | 0% | 200.0 | 41,391 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 204.17 per share. | 04 Mar 2026 | 200 | 40,869 (0%) | 0% | 204.2 | 40,834 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 197.70 per share. | 04 Mar 2026 | 100 | 41,769 (0%) | 0% | 197.7 | 19,770 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 199.01 per share. | 04 Mar 2026 | 100 | 41,669 (0%) | 0% | 199.0 | 19,901 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 200.62 per share. | 04 Mar 2026 | 93 | 41,369 (0%) | 0% | 200.6 | 18,658 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 21,525 | 21,525 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2026 | 4,513 | 41,382 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2026 | 8,810 | 43,338 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2026 | 6,928 | 37,739 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.83 per share. | 14 Feb 2026 | 4,083 | 39,255 (0%) | 0% | 183.8 | 750,578 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.83 per share. | 14 Feb 2026 | 3,211 | 34,528 (0%) | 0% | 183.8 | 590,278 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.83 per share. | 14 Feb 2026 | 992 | 36,869 (0%) | 0% | 183.8 | 182,359 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.83 per share. | 14 Feb 2026 | 801 | 37,861 (0%) | 0% | 183.8 | 147,248 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 183.83 per share. | 14 Feb 2026 | 593 | 38,662 (0%) | 0% | 183.8 | 109,011 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 150.06 per share. | 10 Aug 2025 | 1,325 | 30,811 (0%) | 0% | 150.1 | 198,830 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Other type of transaction at price $ 91.08 per share. | 30 Jun 2025 | 233 | 32,136 (0%) | 0% | 91.1 | 21,221 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 114.08 per share. | 23 Jun 2025 | 500 | 31,903 (0%) | 0% | 114.1 | 57,042 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 114.54 per share. | 10 Jun 2025 | 500 | 32,403 (0%) | 0% | 114.5 | 57,271 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 28,043 | 28,043 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 6,415 | 34,783 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 6,928 | 29,462 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 5,429 | 32,116 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 2,775 | 26,687 (0%) | 0% | 120 | 333,000 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 1,758 | 30,358 (0%) | 0% | 120 | 210,960 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 1,114 | 29,244 (0%) | 0% | 120 | 133,680 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 120.00 per share. | 14 Feb 2025 | 876 | 28,368 (0%) | 0% | 120 | 105,120 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Sep 2024 | 2,000 | 70,944 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 99.60 per share. | 23 Sep 2024 | 2,000 | 22,534 (0%) | 0% | 99.6 | 199,201 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 23 Sep 2024 | 2,000 | 24,534 (0%) | 0% | 52.3 | 104,540 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 106.39 per share. | 28 Aug 2024 | 1,500 | 22,534 (0%) | 0% | 106.4 | 159,591 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Aug 2024 | 1,500 | 61,444 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 28 Aug 2024 | 1,500 | 24,034 (0%) | 0% | 52.3 | 78,405 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Sale of securities on an exchange or to another person at price $ 104.00 per share. | 10 Aug 2024 | 1,000 | 32,903 (0%) | 0% | 104 | 104,000 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CLO & Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.15 per share. | 10 Aug 2024 | 897 | 21,637 (0%) | 0% | 100.2 | 89,839 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | Chief Legal Officer & | Other type of transaction at price $ 60.71 per share. | 28 Jun 2024 | 329 | 22,534 (0%) | 0% | 60.7 | 19,973 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | Chief Legal Officer & | Exercise or conversion of derivative security received from the company (such as an option) at price $ 52.27 per share. | 09 May 2024 | 10,000 | 32,205 (0%) | 0% | 52.3 | 522,700 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | Chief Legal Officer & | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2024 | 10,000 | 62,944 | - | - | Non-Qualified Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | Chief Legal Officer & | Sale of securities on an exchange or to another person at price $ 83.04 per share. | 09 May 2024 | 10,000 | 22,205 (0%) | 0% | 83.0 | 830,449 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CHIEF LEGAL OFFICER & | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 29,272 | 29,272 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CHIEF LEGAL OFFICER & | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 7,208 | 22,205 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Reardon Andrew | CHIEF LEGAL OFFICER & | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.65 per share. | 15 Feb 2024 | 593 | 14,997 (0%) | 0% | 74.6 | 44,267 | Common Stock |
| Ligand Pharma Inc (Class B) | Reardon Andrew | CHIEF LEGAL OFFICER & | Other type of transaction at price $ 60.71 per share. | 29 Dec 2023 | 179 | 15,590 (0%) | 0% | 60.7 | 10,867 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | CHIEF LEGAL OFFICER & | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.73 per share. | 10 Aug 2023 | 897 | 15,411 (0%) | 0% | 68.7 | 61,651 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | See Remarks | Sale of securities on an exchange or to another person at price $ 69.92 per share. | 24 Mar 2023 | 300 | 16,308 (0%) | 0% | 69.9 | 20,977 | Common Stock |
| Ligand Pharma Inc (Class B) | Andrew Reardon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 15,393 | 15,393 | - | - | Employee Stock Option (right to buy) | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 5,668 | 16,608 (0%) | 0% | 0 | Common Stock | |
| Ligand Pharma Inc (Class B) | Andrew Reardon | See Remarks | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.90 per share. | 30 Nov 2022 | 1,073 | 10,940 (0%) | 0% | 72.9 | 78,222 | Common Stock |